Phase 2 HIV and AIDS Trial, Recruiting (NCT06034938)

Phase 2 HIV and AIDS Trial, Recruiting NCT06034938 Sponsor: University Hospital, Caen Condition: HIV and AIDS

Printed from Voxsanity (voxsanity.com.au) — NCT06034938 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hiv Aids

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are an adult living with HIV
You have been on a stable HIV treatment regimen for at least 3 months
Your HIV virus levels in the blood have been undetectable (below 50 copies/mL) for at least 6 months
A past HIV resistance test on your blood showed a specific genetic change in the virus called M184V/I, but a more recent test on your current virus DNA did not show this change (confirm with trial site)
You are willing and able to sign a consent form to take part

Who may not be able to join:

A past resistance test has shown that your HIV has genetic changes that would make it resistant to either of the study medications, doravirine (DOR) or tenofovir (TDF), based on a specific medical scoring system (confirm with trial site)
You have a medical reason why you cannot take the study drugs doravirine, tenofovir, or lamivudine
You have a known allergy or sensitivity to doravirine, tenofovir, lamivudine, or any of their ingredients (including lactose in particular)
You are currently taking or have recently taken a type of medication known as a "strong CYP3A4 inducer," which can interfere with how certain drugs work (confirm with trial site)
You are currently breastfeeding
You are already taking doravirine as part of your current treatment
You are pregnant or breastfeeding
You are under a legal guardianship or trusteeship arrangement

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +33231064320

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06034938

Sponsor: University Hospital, Caen

Phase: Phase 2

Status: Recruiting

Condition: HIV and AIDS

Trial contact: +33231064320

More information: https://clinicaltrials.gov/study/NCT06034938

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are an adult living with HIV
You have been on a stable HIV treatment regimen for at least 3 months
Your HIV virus levels in the blood have been undetectable (below 50 copies/mL) for at least 6 months
A past HIV resistance test on your blood showed a specific genetic change in the virus called M184V/I, but a more recent test on your current virus DNA did not show this change (confirm with trial site)
You are willing and able to sign a consent form to take part

Who may not be able to join:

A past resistance test has shown that your HIV has genetic changes that would make it resistant to either of the study medications, doravirine (DOR) or tenofovir (TDF), based on a specific medical scoring system (confirm with trial site)
You have a medical reason why you cannot take the study drugs doravirine, tenofovir, or lamivudine
You have a known allergy or sensitivity to doravirine, tenofovir, lamivudine, or any of their ingredients (including lactose in particular)
You are currently taking or have recently taken a type of medication known as a "strong CYP3A4 inducer," which can interfere with how certain drugs work (confirm with trial site)
You are currently breastfeeding
You are already taking doravirine as part of your current treatment
You are pregnant or breastfeeding
You are under a legal guardianship or trusteeship arrangement

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University Hospital, Caen

Registry

ClinicalTrials.gov

Start date

8 February 2024

Est. completion

1 April 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Plasma HIV-RNA at 24-week

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov